ARCHIVED - Recommendations on a Human Papillomavirus Immunization Program
Appendix 2: Table 1b
Table 1b: HPV vaccine cost-effectiveness studies, base case assumptions
| Assumption | Sanders(36) |
Kulasingam(35) |
Goldie(38) |
Brisson(40) |
Taira(30) |
Elbasha(32) |
Marra(34) |
| Reduction in cervical cancer-related mortality | 21% |
_ |
_ |
_ |
_ |
_ |
_ |
| Reduction in cervical cancer cases | 20% |
15% |
60% |
62% |
62% female |
78% female |
14% female F14 |
| Reduction in precancer lesions |
|||||||
| CIN 1 | _ |
_ |
_ |
24% |
_ |
_ |
_ |
| CIN 2/3 | 21% |
_ |
_ |
47% |
_ |
_ |
_ |
| Reduction in HPV infections | 13% |
_ |
_ |
_ |
95% female |
_ |
75% female F14 |
| Costs |
|||||||
| No vaccination | $39,682 |
$822 |
$1,111 |
_ |
$40,423 |
$72,659,302 |
$1,368,958,619 |
| Vaccination | $39,928 |
$973 |
$1,400 |
7.2 million (Q) |
$40 667 |
$74,042,990 |
$1,657,060,138 |
| Change in Cost | $246 |
_ |
$289 |
4.4 million (B) |
$244 |
$1,383,687 |
$288,101,519 |
| Life years gained |
|||||||
| No vaccination | 28.785 yr |
28.756 yr |
_ |
_ |
28.798 yr |
_ |
_ |
| Vaccination | 28.793 yr |
28.758 yr |
_ |
_ |
28.811 yr |
_ |
_ |
| Change in LYG | 2.8 yr |
_ |
_ |
1,321 yr |
5.0 yr |
_ |
_ |
| Quality-adjusted life years gained |
|||||||
| No vaccination | 27.720 yr |
_ |
25.982 yr |
_ |
27.742 yr |
2,698,711 yr |
49,370,060 yr |
| Vaccination | 27.731 yr |
_ |
25.993 yr |
_ |
27.759 yr |
2,699,178 yr |
49,381,805 yr |
| Change in QALY | 4.0 yr |
_ |
_ |
1,079 yr |
6.1 yr |
467 yr |
11,744 yr |
| Cost/LYG | $32,066 |
$92,667 |
_ |
$34,496 |
$17,802 |
_ |
_ |
| Cost/QALY | $22,755 |
_ |
$24,300 |
$20,512 Q |
$14,583 female |
$2,964 female |
$24,530 female F14 |
*SIL = squamous intraepithelial lesion, CIN = cervical intraepithelial neoplasia, LSIL = low-grade squamous intraepithelial lesion, HSIL = high-grade intraepithelial lesion
Page details
- Date modified: